Clin Cancer Res. 2014 May 1;20(9):2289-99. doi: 10.1158/1078-0432.CCR-13-3085.
Murphy AB1, Nyame Y, Martin IK, Catalona WJ, Hollowell CM, Nadler RB, Kozlowski JM, Perry KT, Kajdacsy-Balla A, Kittles R.
PURPOSE:
The association between vitamin D and prostate biopsy outcomes has not been evaluated. We examine serum vitamin D levels with prostate biopsy results in men with an abnormal prostate-specific antigen and/or digital rectal examination.
EXPERIMENTAL DESIGN:
Serum 25-hydroxyvitamin D (25-OH D) was obtained from 667 men, ages 40 to 79 years, prospectively enrolled from Chicago urology clinics undergoing first prostate biopsy. Logistic regression was used to evaluate the associations between 25-OH D status and incident prostate cancer, Gleason score, and tumor stage.
RESULTS:
Among European American (EA) men, there was an association of 25-OH D <12 ng/mL with
- higher Gleason score ≥ 4+4 [OR, 3.66; 95% confidence interval (CI), 1.41-9.50; P = 0.008] and
- tumor stage [stage ≥ cT2b vs. ≤ cT2a, OR, 2.42 (1.14-5.10); P = 0.008].
In African American (AA) men, we find
- increased odds of prostate cancer diagnosis on biopsy with 25-OH D < 20 ng/mL [OR, 2.43 (1.20-4.94); P = 0.01].
AA men demonstrated an association between 25-OH D
- < 12 ng/mL and Gleason ≥ 4+4 [OR, 4.89 (1.59-15.07); P = 0.006].
There was an association with tumor stage ≥ cT2b vs. ≤ cT2a [OR, 4.22 (1.52-11.74); P = 0.003].
CONCLUSIONS:
In AA men, vitamin D deficiency was associated with increased odds of prostate cancer diagnosis on biopsy. In both EA and AA men, severe deficiency was positively associated with higher Gleason grade and tumor stage.
©2014 AACR.
PMID: 24789033
Download the PDF from Vitamin D Life
Download comment on this study by Dr. Grant from Vitamin D Life
See also Vitamin D Life
- Cancer - Prostate category overview with extensive associated searches